| Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma S George, D Miao, GD Demetri, D Adeegbe, SJ Rodig, S Shukla, ... Immunity 46 (2), 197-204, 2017 | 451 | 2017 |
| Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma CD Carey, D Gusenleitner, M Lipschitz, MGM Roemer, EC Stack, E Gjini, ... Blood, The Journal of the American Society of Hematology 130 (22), 2420-2430, 2017 | 303 | 2017 |
| Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity CA Jacobson, BD Hunter, R Redd, SJ Rodig, PH Chen, K Wright, ... Journal of Clinical Oncology 38 (27), 3095, 2020 | 256 | 2020 |
| Angiopoietin-2 as a biomarker and target for immune checkpoint therapy X Wu, A Giobbie-Hurder, X Liao, C Connelly, EM Connolly, J Li, ... Cancer immunology research 5 (1), 17-28, 2017 | 143 | 2017 |
| Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer AK Mehta, EM Cheney, CA Hartl, C Pantelidou, M Oliwa, JA Castrillon, ... Nature cancer 2 (1), 66-82, 2021 | 142 | 2021 |
| Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell–rich and exhausted T-effector microenvironment FZ Cader, RCJ Schackmann, X Hu, K Wienand, R Redd, B Chapuy, ... Blood, The Journal of the American Society of Hematology 132 (8), 825-836, 2018 | 136 | 2018 |
| The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative SS Patel, JL Weirather, M Lipschitz, A Lako, PH Chen, GK Griffin, ... Blood, The Journal of the American Society of Hematology 134 (23), 2059-2069, 2019 | 107 | 2019 |
| Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity CA Jacobson, B Hunter, P Armand, Y Kamihara, J Ritz, SJ Rodig, ... Blood 132, 92, 2018 | 104 | 2018 |
| The immune microenvironment in hormone Receptor–Positive breast cancer before and after preoperative chemotherapy AG Waks, DG Stover, JL Guerriero, D Dillon, WT Barry, E Gjini, C Hartl, ... Clinical Cancer Research 25 (15), 4644-4655, 2019 | 81 | 2019 |
| Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy PH Chen, M Lipschitz, JL Weirather, C Jacobson, P Armand, K Wright, ... JCI insight 5 (12), 2020 | 75 | 2020 |
| Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma GK Griffin, JL Weirather, MGM Roemer, M Lipschitz, A Kelley, PH Chen, ... Blood, The Journal of the American Society of Hematology 137 (10), 1353-1364, 2021 | 35 | 2021 |
| Evaluating the PD-1 axis and immune effector cell infiltration in oropharyngeal squamous cell carcinoma JD Schoenfeld, E Gjini, SJ Rodig, RB Tishler, B Rawal, PJ Catalano, ... International Journal of Radiation Oncology* Biology* Physics 102 (1), 137-145, 2018 | 28 | 2018 |
| Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients Y Boucher, AS Kumar, JM Posada, E Gjini, K Pfaff, M Lipschitz, A Lako, ... NPJ precision oncology 5 (1), 62, 2021 | 24 | 2021 |
| Multiparametric in situ imaging of NPM1-mutated acute myeloid leukemia reveals prognostically-relevant features of the marrow microenvironment SS Patel, M Lipschitz, GS Pinkus, JL Weirather, O Pozdnyakova, ... Modern Pathology 33 (7), 1380-1388, 2020 | 11 | 2020 |
| Mass cytometry of Hodgkin lymphoma reveals a CD4 (+) exhausted T-effector and T-regulatory cell rich microenvironment FZ Cader, RCJ Schackmann, X Hu, K Wienand, R Redd, B Chapuy, ... Blood 132 (8), 2018 | 11 | 2018 |
| Clinical and biological evaluation of the novel CD30/CD16A tetravalent bispecific antibody (AFM13) in relapsed or refractory CD30-positive lymphoma with cutaneous presentation … A Sawas, PH Chen, M Lipschitz, S Rodig, G Vlad Blood 136, 25-26, 2020 | 9 | 2020 |
| Clinical and biological evaluation of the novel CD30/CD16A tetravalent bispecific antibody (AFM13) in relapsed or refractory CD30-positive lymphoma with cutaneous presentation … A Sawas, H Elgedawe, G Vlad, M Lipschitz, PH Chen, SJ Rodig, JK Lue, ... Blood 132, 2908, 2018 | 9 | 2018 |
| Clinical and biological evaluation of the novel CD30/CD16A tetravalent bispecific antibody (AFM13) in relapsed or refractory CD30‐positive lymphoma with cutaneous presentation … A Sawas, P Chen, G Vlad, M Lipschitz, M Abdul‐Hay, J Lue, C Deng, ... Hematological Oncology 37, 314-316, 2019 | 8 | 2019 |
| Analysis of CAR-T and immune cells within the tumor micro-environment of diffuse large B-cell lymphoma post CAR-T treatment by multiplex immunofluorescence PH Chen, M Lipschitz, K Wright, P Armand, CA Jacobson, ZJ Roberts, ... Blood 132, 678, 2018 | 7 | 2018 |
| PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation P Armand, YB Chen, RA Redd, RM Joyce, J Bsat, RW Merryman, ... Blood 132, 1650, 2018 | 3 | 2018 |
